Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.05.015 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Heejoo Ko und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea. Electronic address: kohjoo7@c…. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasms, Second Primary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: In light of improved survival rates among multiple myeloma (MM) survivors, we sought to assess their risk of secondary malignancies compared to the general population. MATERIALS AND METHODS: This nationwide population-based case-control cohort study utilized the Korea National Health Insurance Service (KNHIS) database incorporating data from 2009 to 2020. We analyzed a total of 7348 patients diagnosed with MM in the case cohort. We selected a control group of 29,351 individuals from the general population without MM, employing a 1:4 propensity score matching approach. Matching criteria included age, sex, and comorbidities to ensure a balanced and reliable comparison. RESULTS: The cumulative incidence of any secondary malignancy was significantly higher in the case cohort than the control cohort (Hazard ratio [HR] 1.576, 95% confidence interval [CI], [1.381-1.798]). Hematologic malignancy risk was notably higher in the case cohort (HR 8.026, 95% CI, [5.402-11.924]), especially therapy-related myeloid neoplasms (t-MN) (HR 12.063, 95% CI, [6.839-21.278]). No significant difference was shown in nonhematologic malignancy incidence. In subgroup analysis, transplant-eligible MM patients had a significantly higher incidence of any secondary malignancy (HR 1.104, 95% CI, [1.003-1.214]) than transplant-ineligible patients. The incidence of secondary malignancy in MM patients in the lenalidomide-available era was not significantly increased compared to the prelenalidomide era. CONCLUSION: While hematologic malignancies, particularly t-MN, are significantly elevated in MM patients compared to general population, nonhematologic malignancies do not appear to be significantly elevated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea. Electronic address: kohjoo7@catholic.ac.kr.
- Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea. Electronic address: waystolove@catholic.ac.kr.
- Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
- Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Jongro-gu, Seoul, Republic of Korea.
Zitieren
APA
Ko, H., Han, S., Park, S. S., Choi, S., Byun, J. M., & Min, C. K. (2024). Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.015
Vancouver
Ko H, Han S, Park SS, Choi S, Byun JM, Min CK. Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.015
BibTeX
@article{Ko2024,
author = {Ko, Heejoo and Han, Seunghoon and Park, Sung-Soo and Choi, Suein and Byun, Ja Min and Min, Chang-Ki},
title = {Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.05.015}
}
EUVIMED